Healthcare information provider Wolters Kluwer Health is enhancing its industry-leading pharmacogenomics content across its clinical drug information solutions. This greater depth of pharmacogenomics content is now included in the databases and application programming interfaces (APIs) of Wolters Kluwer Health's embedded drug data solution, Medi-Span®, and is accessible through its premier online and mobile drug references, Lexicomp® Online™ and Lexicomp Mobile Apps.
Drug information monographs within Lexicomp Online and Mobile Apps now include three new fields of information on pharmacogenomics, or the study of how genes affect a person's response to drugs. The new fields examine whether gene testing is required, recommended or to be considered for a specific drug therapy. Reference links within the monographs allow users to instantly access more detailed content from the in-depth Lexicomp proprietary pharmacogenomics database.
Medi-Span incorporates the same information into its drug and disease contraindications screening functions, providing clinicians with alerts when a prescribed medication may be affected by a patient's genetic variation. Enabling the addition of pharmacogenomic information in the electronic health record during order entry can improve patient safety by preventing adverse drug events.
